Published in J Clin Microbiol on January 01, 1986
Correlates of protection induced by vaccination. Clin Vaccine Immunol (2010) 5.21
Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med (2006) 3.71
Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol (1986) 3.33
Influence of prior influenza vaccination on antibody and B-cell responses. PLoS One (2008) 2.83
Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med (1995) 2.26
Impaired Antibody-mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus. Am J Respir Crit Care Med (2015) 1.65
High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults. J Clin Microbiol (1994) 1.61
A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults. Vaccine (2009) 1.56
Analysis of immunoglobulin G antibody responses after administration of live and inactivated influenza A vaccine indicates that nasal wash immunoglobulin G is a transudate from serum. J Clin Microbiol (1987) 1.53
Blocking interhost transmission of influenza virus by vaccination in the guinea pig model. J Virol (2009) 1.50
Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus. J Virol (1995) 1.45
Antibody dynamics of 2009 influenza A (H1N1) virus in infected patients and vaccinated people in China. PLoS One (2011) 1.36
Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults. Clin Diagn Lab Immunol (1996) 1.36
Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens. Infect Immun (2000) 1.35
Time to peak serum antibody response to influenza vaccine in the elderly. Clin Diagn Lab Immunol (1996) 1.22
Resistance of adults to challenge with influenza A wild-type virus after receiving live or inactivated virus vaccine. J Clin Microbiol (1986) 1.22
H5N1 vaccines in humans. Virus Res (2013) 1.16
B cell response and hemagglutinin stalk-reactive antibody production in different age cohorts following 2009 H1N1 influenza virus vaccination. Clin Vaccine Immunol (2013) 1.13
Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines. J Clin Microbiol (1989) 1.12
Nasal-associated lymphoid tissue is a site of long-term virus-specific antibody production following respiratory virus infection of mice. J Virol (2001) 1.06
Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine. Vaccine (2009) 1.05
The influence of the multi-basic cleavage site of the H5 hemagglutinin on the attenuation, immunogenicity and efficacy of a live attenuated influenza A H5N1 cold-adapted vaccine virus. Virology (2009) 1.01
Active synthesis of hemagglutinin-specific immunoglobulin A by lung cells of mice that were immunized intragastrically with inactivated influenza virus vaccine. J Virol (1987) 1.00
Impact of prior seasonal H3N2 influenza vaccination or infection on protection and transmission of emerging variants of influenza A(H3N2)v virus in ferrets. J Virol (2013) 0.91
Serum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization. J Virol (2001) 0.91
Local and systemic antibody responses in high-risk adults given live-attenuated and inactivated influenza A virus vaccines. J Clin Microbiol (1988) 0.91
Longevity of B-cell and T-cell responses after live attenuated influenza vaccination in children. J Infect Dis (2014) 0.91
Rapid method for detection of influenza a and B virus antigens by use of a two-photon excitation assay technique and dry-chemistry reagents. J Clin Microbiol (2007) 0.89
Use of live cold-adapted influenza A H1N1 and H3N2 virus vaccines in seropositive adults. J Clin Microbiol (1990) 0.88
In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory. J Clin Microbiol (1991) 0.88
Heightened adaptive immune responses following vaccination with a temperature-sensitive, live-attenuated influenza virus compared to adjuvanted, whole-inactivated virus in pigs. Vaccine (2012) 0.87
A cell culture-derived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individuals. Clin Infect Dis (2012) 0.87
Flexible label-free quantitative assay for antibodies to influenza virus hemagglutinins. Clin Vaccine Immunol (2010) 0.86
Implications of broadly neutralizing antibodies in the development of a universal influenza vaccine. Curr Opin Virol (2016) 0.85
Repeated influenza vaccination of healthy children and adults: borrow now, pay later? Epidemiol Infect (2006) 0.84
Isotype-specific enzyme immunoassay for influenza antibody with monoclonal antibodies to human immunoglobulins. J Clin Microbiol (1986) 0.84
The human side of influenza. J Leukoc Biol (2012) 0.83
Long term persistence of IgE anti-influenza virus antibodies in pediatric and adult serum post vaccination with influenza virus vaccine. Int J Med Sci (2011) 0.83
Distinct cross-reactive B-cell responses to live attenuated and inactivated influenza vaccines. J Infect Dis (2014) 0.82
Targeting RSV with vaccines and small molecule drugs. Infect Disord Drug Targets (2012) 0.81
Intranasal delivery of group B meningococcal native outer membrane vesicle vaccine induces local mucosal and serum bactericidal antibody responses in rabbits. Infect Immun (2005) 0.80
Characterization of reverse genetics-derived cold-adapted master donor virus A/Leningrad/134/17/57 (H2N2) and reassortants with H5N1 surface genes in a mouse model. Clin Vaccine Immunol (2014) 0.80
A Single Dose of an Avian H3N8 Influenza Virus Vaccine Is Highly Immunogenic and Efficacious against a Recently Emerged Seal Influenza Virus in Mice and Ferrets. J Virol (2015) 0.79
A controlled clinical study of the effect of nasal immunization with a Streptococcus mutans antigen alone or incorporated into liposomes on induction of immune responses. Infect Immun (1999) 0.79
Induction and maintenance of anti-influenza antigen-specific nasal secretory IgA levels and serum IgG levels after influenza infection in adults. Influenza Other Respir Viruses (2012) 0.79
Evaluation of cold-recombinant influenza A/Korea (CR-59) virus vaccine in infants. J Clin Microbiol (1989) 0.78
Replicating Single-cycle Adenovirus Vectors Generate Amplified Influenza Vaccine Responses. J Virol (2016) 0.78
Antibody Persistence in Adults Two Years after Vaccination with an H1N1 2009 Pandemic Influenza Virus-Like Particle Vaccine. PLoS One (2016) 0.77
Oral Fluids as a Live-Animal Sample Source for Evaluating Cross-Reactivity and Cross-Protection following Intranasal Influenza A Virus Vaccination in Pigs. Clin Vaccine Immunol (2015) 0.76
Impact of Estrogen Therapy on Lymphocyte Homeostasis and the Response to Seasonal Influenza Vaccine in Post-Menopausal Women. PLoS One (2016) 0.76
Lack of PD-L1 expression by iNKT cells improves the course of influenza A infection. PLoS One (2013) 0.76
Collectivism/individualism and its relationship to behavioral and physiological immunity. Health Psychol Behav Med (2014) 0.75
A novel particulate influenza vaccine induces long-term and broad-based immunity in mice after oral immunization. J Virol (1992) 0.75
Live Attenuated Influenza Vaccine in Children Induces B-Cell Responses in Tonsils. J Infect Dis (2016) 0.75
Comparisons of the Humoral and Cellular Immune Responses Induced by Live Attenuated Influenza Vaccine (LAIV) and Inactivated Influenza Vaccine (IIV) in Adults. Clin Vaccine Immunol (2016) 0.75
Nasal IgA Provides Protection against Human Influenza Challenge in Volunteers with Low Serum Influenza Antibody Titre. Front Microbiol (2017) 0.75
Mucosal immunology. Immunology (1980) 3.84
Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ's Hospital. Lancet (1979) 3.55
Mucosal and glandular distribution of immunoglobulin components. Immunohistochemistry with a cold ethanol-fixation technique. Immunology (1974) 3.47
Hemagglutinin-specific enzyme-linked immunosorbent assay for antibodies to influenza A and B viruses. J Clin Microbiol (1981) 3.46
Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines. Infect Immun (1982) 2.61
Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity. Eur J Immunol (1984) 2.57
Protection of infants from infection with influenza A virus by transplacentally acquired antibody. J Infect Dis (1980) 2.50
Evaluation of influenza A/Hong Kong/123/77 (H1N1) ts-1A2 and cold-adapted recombinant viruses in seronegative adult volunteers. Infect Immun (1980) 2.42
Dose response of A/Alaska/6/77 (H3N2) cold-adapted reassortant vaccine virus in adult volunteers: role of local antibody in resistance to infection with vaccine virus. Infect Immun (1983) 2.01
Antibody response in respiratory secretions of volunteers given live and dead influenza virus. J Immunol (1968) 1.92
A RATIONALE FOR STUDIES IN THE CONTROL OF EPIDEMIC INFLUENZA. Science (1943) 1.89
Comparison of long-term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine. J Med Virol (1985) 1.88
Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection. Lancet (1984) 1.88
Subclass distribution and molecular form of immunoglobulin A hemagglutinin antibodies in sera and nasal secretions after experimental secondary infection with influenza A virus in humans. J Clin Microbiol (1985) 1.80
Serum antibody prevents lethal murine influenza pneumonitis but not tracheitis. Infect Immun (1979) 1.79
Cold-adapted recombinant influenza A virus vaccines in seronegative young children. J Infect Dis (1982) 1.61
Studies on inactivated influenza vaccines. II. Effect of increasing dosage on antibody response and adverse reactions in man. Am J Epidemiol (1970) 1.60
Dose response of cold-adapted, reassortant influenza A/California/10/78 virus (H1N1) in adult volunteers. J Infect Dis (1984) 1.57
Hemagglutinin-specific antibody responses in immunoglobulin G, A, and M isotypes as measured by enzyme-linked immunosorbent assay after primary or secondary infection of humans with influenza A virus. Infect Immun (1983) 1.56
Changes in IgA and IgG concentrations in nasal secretions prior to the appearance of antibody during viral respiratory infection in man. J Immunol (1970) 1.49
Local and systemic immunity to influenza infections in ferrets. Infect Immun (1978) 1.43
Dose response of influenza A/Washington/897/80 (H3N2) cold-adapted reassortant virus in adult volunteers. J Infect Dis (1984) 1.37
Cold-recombinant influenza A/California/10/78 (H1N1) virus vaccine (CR-37) in seronegative children: infectivity and efficacy against investigational challenge. J Infect Dis (1984) 1.28
Humoral and cellular immune responses of seronegative children vaccinated with a cold-adapted influenza A/HK/123/77 (H1N1) recombinant virus. Infect Immun (1980) 1.19
Review of existing vaccines for influenza. Am J Clin Pathol (1978) 1.09
A comparison of live and inactivated influenza A (H1N1) virus vaccines. 1. Short-term immunity. J Hyg (Lond) (1983) 1.07
A comparison of live and inactivated influenza A (H1N1) virus vaccines. 2. Long-term immunity. J Hyg (Lond) (1983) 1.06
Immune responses in serum and respiratory secretions following vaccination with a live cold-recombinant (CR35) and inactivated A/USSR/77 (H1N1) influenza virus vaccine. J Med Virol (1983) 1.03
Immunity to influenza in ferrets. XIV: Comparative immunity following infection or immunization with live or inactivated vaccine. Br J Exp Pathol (1981) 0.98
Revised (1972-1973) bivalent influenza vaccine. Serum and nasal antibody responses to parenteral vaccination. JAMA (1973) 0.94
Human influenza: aspects of the immune response to vaccination. Ann Intern Med (1969) 0.94
Antibody decline in children following A/New Jersey/76 influenza virus immunization. J Pediatr (1980) 0.93
Biological, genetic and biochemical characterization of a cold-adapted recombinant A/Victoria/3/75 virus and its evaluation in volunteers. Dev Biol Stand (1978) 0.91
A single amino acid in the PB2 gene of influenza A virus is a determinant of host range. J Virol (1993) 10.22
The diarrheal response of humans to some classic serotypes of enteropathogenic Escherichia coli is dependent on a plasmid encoding an enteroadhesiveness factor. J Infect Dis (1985) 9.18
New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol Rev (1983) 7.16
Experimental Campylobacter jejuni infection in humans. J Infect Dis (1988) 7.05
Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc Natl Acad Sci U S A (1995) 6.51
Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc Natl Acad Sci U S A (1983) 4.69
Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex. Am J Epidemiol (1973) 4.47
Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques. Infect Immun (1988) 4.44
Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc Natl Acad Sci U S A (1986) 4.14
Temperature-sensitive mutants of influenza virus. 3. Further characterization of the ts-1(E) influenza A recombinant (H3N2) virus in man. J Infect Dis (1973) 3.89
Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus. J Virol (1986) 3.64
Coli surface antigens 1 and 3 of colonization factor antigen II-positive enterotoxigenic Escherichia coli: morphology, purification, and immune responses in humans. Infect Immun (1984) 3.63
Duration of infection-derived immunity to cholera. J Infect Dis (1981) 3.60
Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoprotein. Proc Natl Acad Sci U S A (1986) 3.53
Association of serum anti-neuraminidase antibody with resistance to influenza in man. N Engl J Med (1972) 3.51
Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc Natl Acad Sci U S A (1997) 3.49
Hemagglutinin-specific enzyme-linked immunosorbent assay for antibodies to influenza A and B viruses. J Clin Microbiol (1981) 3.46
Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol (1986) 3.33
Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae. J Infect Dis (1982) 3.28
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst (2001) 3.28
Virulence of avian influenza A viruses for squirrel monkeys. Infect Immun (1982) 3.22
Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci U S A (1997) 3.02
Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis (2000) 2.90
Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. J Virol (1999) 2.80
Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. Am J Trop Med Hyg (2001) 2.67
Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines. Infect Immun (1982) 2.61
An influenza A virus containing influenza B virus 5' and 3' noncoding regions on the neuraminidase gene is attenuated in mice. Proc Natl Acad Sci U S A (1991) 2.55
Use of single-gene reassortant viruses to study the role of avian influenza A virus genes in attenuation of wild-type human influenza A virus for squirrel monkeys and adult human volunteers. J Clin Microbiol (1992) 2.50
Evaluation in humans of attenuated Vibrio cholerae El Tor Ogawa strain Texas Star-SR as a live oral vaccine. Infect Immun (1984) 2.48
Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol (1986) 2.43
Evaluation of influenza A/Hong Kong/123/77 (H1N1) ts-1A2 and cold-adapted recombinant viruses in seronegative adult volunteers. Infect Immun (1980) 2.42
Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines. J Virol (1988) 2.35
Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells. J Virol (1992) 2.35
New enzyme immunoassays for measurement of influenza A/Victoria/3/75 virus in nasal washes. Lancet (1980) 2.35
The B allele of the NS gene of avian influenza viruses, but not the A allele, attenuates a human influenza A virus for squirrel monkeys. Virology (1989) 2.32
Temperature-sensitive mutants of influenza virus. II. Attenuation of ts recombinants for man. J Infect Dis (1972) 2.28
Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity. J Virol (1987) 2.26
Recovery of infectious human parainfluenza virus type 3 from cDNA. Virology (1997) 2.17
Rescue of an influenza A virus wild-type PB2 gene and a mutant derivative bearing a site-specific temperature-sensitive and attenuating mutation. J Virol (1993) 2.15
The pathogenicity of nonenterotoxigenic Vibrio cholerae serogroup O1 biotype El Tor isolated from sewage water in Brazil. J Infect Dis (1982) 2.13
Temperature-sensitive mutants of influenza A virus. XII. Safety, antigenicity, transmissibility, and efficacy of influenza A/Udorn/72-ts-1[E] recombinant viruses in human adults. J Infect Dis (1976) 2.12
Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection. J Clin Microbiol (1986) 2.09
Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. Vaccine (1995) 2.06
Evaluation of avian-human reassortant influenza A/Washington/897/80 x A/Pintail/119/79 virus in monkeys and adult volunteers. J Clin Microbiol (1986) 2.06
Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J Virol (1991) 2.05
Dose response of A/Alaska/6/77 (H3N2) cold-adapted reassortant vaccine virus in adult volunteers: role of local antibody in resistance to infection with vaccine virus. Infect Immun (1983) 2.01
Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. J Virol (2000) 1.97
Antigenic variation in the hemagglutinin-neuraminidase protein of human parainfluenza type 3 virus. Virology (1985) 1.90
Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine. J Infect Dis (1987) 1.90
Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin. Infect Immun (1987) 1.89
Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection. Lancet (1984) 1.88
Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis (1997) 1.86
Reassortant virus derived from avian and human influenza A viruses is attenuated and immunogenic in monkeys. Science (1982) 1.86
Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine (1996) 1.86
A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes. Am J Trop Med Hyg (2001) 1.85
Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol (1990) 1.82
Cold adapted variants of influenza A. II. Comparison of the genetic and biological properties of ts mutants and recombinants of the cold adapted A/AA/6/60 strain. Arch Virol (1977) 1.81
Subclass distribution and molecular form of immunoglobulin A hemagglutinin antibodies in sera and nasal secretions after experimental secondary infection with influenza A virus in humans. J Clin Microbiol (1985) 1.80
Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection. J Clin Microbiol (1986) 1.79
Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine. Science (1990) 1.78
Use of the enzyme-linked immunosorbent assay to detect serum antibody responses of volunteers who received attenuated influenza A virus vaccines. Infect Immun (1980) 1.77
Avian-human reassortant influenza A viruses derived by mating avian and human influenza A viruses. J Infect Dis (1984) 1.77
Dose response of influenza A/Washington/897/80 (H3N2) avian-human reassortant virus in adult volunteers. J Infect Dis (1985) 1.76
Studies of passive immunotherapy for infections of respiratory syncytial virus in the respiratory tract of a primate model. J Infect Dis (1985) 1.71
Temperature-sensitive mutants of influenza virus. IV. Induction of interferon in the nasopharynx by wild-type and a temperature-sensitive recombinant virus. J Infect Dis (1973) 1.70
Host range mutants of an influenza A virus. Arch Virol (1978) 1.69
Altered tissue tropism of human-avian reassortant influenza viruses. Virology (1983) 1.69
Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. J Infect Dis (1993) 1.67
Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity. J Virol (1987) 1.67
Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees. J Virol (1998) 1.66
The systemic and mucosal immune response of humans to influenza A virus. Curr Top Microbiol Immunol (1989) 1.62
Measles virus infection in rhesus macaques: altered immune responses and comparison of the virulence of six different virus strains. J Infect Dis (1999) 1.62
Factors modifying host resistance to viral infection. 3. Effect of whole body x-irradiation on experimental encephalomyocarditis virus infection in mice. J Exp Med (1968) 1.61
Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate. Vaccine (2003) 1.61
The influence of human immunodeficiency virus (HIV) infection on antibody responses to influenza vaccines. Ann Intern Med (1988) 1.60
Nucleotide sequence analysis of the respiratory syncytial virus subgroup A cold-passaged (cp) temperature sensitive (ts) cpts-248/404 live attenuated virus vaccine candidate. Virology (1996) 1.60
Development of subtype-specific and heterosubtypic antibodies to the influenza A virus hemagglutinin after primary infection in children. J Clin Microbiol (1985) 1.59
Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines. J Infect Dis (1997) 1.57
Dose response of cold-adapted, reassortant influenza A/California/10/78 virus (H1N1) in adult volunteers. J Infect Dis (1984) 1.57
Hemagglutinin-specific antibody responses in immunoglobulin G, A, and M isotypes as measured by enzyme-linked immunosorbent assay after primary or secondary infection of humans with influenza A virus. Infect Immun (1983) 1.56
Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity. Proc Natl Acad Sci U S A (1992) 1.54